RxDoctor Payments Data

Stephanie Ruiz, APRN

Family · Las Cruces, NMNPI 1639814080

Payments from drug & device makers

$786in general payments, 2019–2025

Across 11 payments — averaging $71.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$230
  • Alpha Cognition USA, Inc.$153
  • Novo Nordisk$132
  • Otsuka America Pharmaceutical, Inc.$97
  • Insulet Corporation$92
  • Lilly USA, LLC$37
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$230
Alpha Cognition USA, Inc.1$153
Novo Nordisk2$132
Otsuka America Pharmaceutical, Inc.1$97
Insulet Corporation1$92
Lilly USA, LLC2$37
Novartis1$24
Tonix Medicines, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$786 in reported general payments places this provider in the 70th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$5,162
Medicare patients
35
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$133,803
TrulicityDulaglutide39$41,143
JardianceEmpagliflozin46$32,681
MounjaroTirzepatide26$29,170
XareltoRivaroxaban26$22,655
OzempicSemaglutide24$22,418
RexultiBrexpiprazole12$14,203
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen386$13,827
Breo ElliptaFluticasone/Vilanterol15$6,509
Oxycodone Hcl303$6,090
Pregabalin243$6,087
FarxigaDapagliflozin Propanediol11$5,917
Naloxone Hcl89$5,839
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,796
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen164$5,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$37$70,31365 claims
Novo NordiskOzempic$132$22,41824 claims
Otsuka America Pharmaceutical, Inc.Rexulti$97$14,20312 claims
GSKBreo Ellipta$230$6,50915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →